All Modules

Appropriate Use of Immune Therapy to Treat Head and Neck Cancer CME Credits: 0.5
While the introduction of cetuximab for treating patients with head and neck carcinomas may have introduced another agent to oncologists, these agents (that target oncogenes) have not yielded a prolonged clinical benefit.
Faculty: David S. Ettinger, MD Expires: 9/7/2018

Metastatic Melanoma: Managing Benefit and Risk with the New Systemic Therapies CME Credits: 0.5
Melanoma is one of the most lethal human cancers and has historically been among the most resistant to contemporary chemotherapeutic approaches. It is the most serious form of skin cancer and has the highest mortality rate of all skin cancer types, leading to a rapid decline in the health in people who often are in the prime of life.
Faculty: William Sharfman, MD, FACP Expires: 5/20/2018